University of Pittsburgh logo
  1. People

Donald P. Taylor, PhD, MBA, CLP

  • Assistant Vice Chancellor, Health Sciences Translation
  • Associate Professor, Department of Biomedical Informatics
  • Executive Director, sciVelo
  • Co-Director, Center for CommercialApplications of Healthcare Data

Dr. Taylor received his BS in information systems from Carnegie Mellon University and his MS and PhD degrees in bioengineering from the Swanson School of Engineering at the University of Pittsburgh. He earned an MBA at Pitt’s Katz Graduate School of Business and conducted postdoctoral research in pathology at Pitt’s School of Medicine.

Donald P. Taylor is Assistant Vice Chancellor for Commercial Translation in the Health Sciences; Co-Director of the Center for Commercial Applications of Healthcare Data and of the Clinical and Translational Science Institute’s Innovation Core; Associate Director of the Center for Medical Innovation; Associate Professor of Biomedical Informatics at the Universtiy of Pittsburgh.  Dr. Taylor also serves as an adjunct Professor of Information Systems as Carnegie Mellon University. His responsibilities include working across the six health sciences schools to accelerate commercial translation of Pitt’s scientific research and inventions, secure commercial translation grant opportunities, and help train the next generation of world-class translational development students, staff, and faculty.

Dr. Taylor previously served as a biotechnology entrepreneur having been with 5 startup companies. He also spent time with Fortune 500 companies such as serving as the global pharmaceutical and biotechnology market segment manager for Thermo Fisher Scientific Inc.

Representative Publications

  1. Taylor DP, Wells JZ, Savol A, Chennubhotla C, Wells A. Modeling boundary conditions for balanced proliferation in metastatic latency. Clin Cancer Res. 2013 Mar 1;19(5):1063-70. PMCID: PMC3594128
  2.  Wells A, Griffith L, Wells JZ, Taylor DP. The dormancy dilemma: quiescence versus balanced proliferation. Cancer Res. 2013;73(13):3811-6. PMCID: PMC3702639
  3.  Yates CC, Nuschke A, Rodrigues M, Whaley D, Dechant JJ, Taylor DP, Wells A. Improved transplanted stem cell survival in a polymer gel supplemented with tenascin-C accelerates healing and reduces scarring of murine skin wounds. Cell Transplant. 2016 Jul 22.
  4. Moussawi S, Quesenberry J, Weinberg R, Sanders M, Lovett M, Heimann L, Sooriamurthi R, Taylor D. "Improving Student-Driven Feedback and Engagement in the Classroom: Evaluating the Effectiveness of the Speed Dating Model". International Journal of Innovation in Education, accepted for publication 2019
  5. Y. Ye, R. D. Boyce, M.K. Davis, K. Elliston, C. Davatzikos, A. Fedorov, J. C. Fillion-Robin, I. Foster, J. Gilbertson, M. Heiskanen, J. Klemm, A. Lasso, J. V. Miller, M. Morgan, S. Pieper, B. Raumann, B. Sarachan, G. Savova, J. C. Silverstein, D. Taylor, J. Zelnis, G. Q. Zhang, M. J. Becich. “Open Source Software Sustainability Models: Initial White Paper from the Informatics Technology for Cancer Research Sustainability and Industry Partnership Work Group”. arXiv:1912.12371, Dec. 2019.

Research Interests

  1. Mechanisms of breast cancer metastatic latency through computational models and human 3D-perfused micro-scale tissue bioreactors
  2. Chronic wound healing
  3. Academic commercial translation

Research Grants

ACTIVE

NIH/NCATS 7/12/2016-5/31/2021
UL1 TR001857-01 (Reis) $35,635
University of Pittsburgh Clinical and Translational Science Institute - Innovation
1) Develop advanced, experiential innovation training, and networking and externship opportunities and support academic career development for biomedical innovators; 2) Develop and disseminate new methods and processes that encourage and support innovative approaches to clinically important problems; and 3) Accelerate clinical commercial translation by providing hands-on domain expertise and leadership.
 
NIH/NIDCR 03/01/2017-02/28/2018
1U24DE0256915-01 (Kohn) $11,878
Michigan-Pittsburgh-Wyss Resource Center Supporting Regenerative Medicine in Dental, Oral and Craniofacial Technologies
The goal of this RC is to translate TE/RM innovations that address the ongoing clinical need to restore or create healthy, functional DOC tissues. We plan to augment the existing extensive foundation of scientific and translational development expertise in the tissue engineering/regenerative medicine (TE/RM) field available at the University of Pittsburgh. Through the robust and coordinated infrastructure of the McGowan Institute for Regenerative Medicine and its Center for Craniofacial Regeneration, we plan to fulfill the mission to catalyze, nurture and expedite the advancement of the most promising technologies in TE/RM to safely and effectively regenerate, reconstruct and restore dental, oral and craniofacial tissue and function.
 
FDA 09/01/2018-08/31/2023
1P50FD006427-01 (Maltese; Pitt: Wagner) $21,716
Pennsylvania Pediatric Device Consortium
As part of our strategic direction for pediatric device development, McGowan will be partnering with the Children’s Hospital of Philadelphia (CHOP), one of seven consortia nationwide currently funded by the FDA, to continue developing pediatric devices as well as build upon an already existing translational ecosystem to translate these technologies from the bench to the bedside and onto commercialization.

PENDING

NIH/Univ of Michigan 04/01/2020-03/31/2025
U24 (Pitt: Sfeir) $60,526
Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center: Advancing Dental, Oral and Craniofacial Regeneration to Clinical Trial Initiation
 
The University of Pittsburgh will provide extensive scientific and translational development expertise through the robust and coordinated infrastructure of the Center for Craniofacial Regeneration at the School of Dental Medicine and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh – among them those at numerous UPitt prototype and translational research development centers -- will focus on guiding technologies to reconstruct and restore dental, oral and craniofacial tissue and function to a state of clinical readiness and, subsequently, regulatory approval.